Article
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial.
ESMO open - 1 May 2020
Vernieri Claudio, Ganzinelli Monica, Rulli Eliana, Farina Gabriella, Bettini Anna Cecilia, Bareggi Claudia, Rosso Lorenzo, Signorelli Diego, Galli Giulia, Lo Russo Giuseppe, Proto Claudia, Moro Massimo, Indraccolo Stefano, Busico Adele, Sozzi Gabriella, Torri Valter, Marabese Mirko, Massimo Broggini, Garassino Marina C
Abstract excerpt
PURPOSE: In patients with advanced lung adenocarcinoma, the impact of LKB1 mutations on cytotoxic chemotherapy efficacy remains poorly explored. Here, we aimed at investigating the potential impact of LKB1 mutational status on chemotherapy efficacy in advanced non-small-cell lung cancer (NSCLC) patients enrolled in the TArceva Italian Lung Optimisation tRial (TAILOR) trial. METHODS: The multicenter TAILOR trial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.